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ABSTRACT
Introduction: Ischaemic heart disease (IHD) is one of
the most common causes of death in the UK and
treatment of patients with IHD costs the National
Health System (NHS) billions of pounds each year.
Allopurinol is a xanthine oxidase inhibitor used to
prevent gout that also has several positive effects
on the cardiovascular system. The ALL-HEART
study aims to determine whether allopurinol
improves cardiovascular outcomes in patients
with IHD.
Methods and analysis: The ALL-HEART study is a
multicentre, controlled, prospective, randomised,
open-label blinded end point (PROBE) trial of
allopurinol (up to 600 mg daily) versus no treatment in
a 1:1 ratio, added to usual care, in 5215 patients aged
60 years and over with IHD. Patients are followed up
by electronic record linkage and annual questionnaires
for an average of 4 years. The primary outcome is the
composite of non-fatal myocardial infarction, non-fatal
stroke or cardiovascular death. Secondary outcomes
include all-cause mortality, quality of life and cost-
effectiveness of allopurinol. The study will end when
631 adjudicated primary outcomes have occurred. The
study is powered at 80% to detect a 20% reduction in
the primary end point for the intervention. Patient
recruitment to the ALL-HEART study started in
February 2014.
Ethics and dissemination: The study received
ethical approval from the East of Scotland
Research Ethics Service (EoSRES) REC 2 (13/ES/
0104). The study is event-driven and results are
expected after 2019. Results will be reported in
peer-reviewed journals and at scientific
meetings. Results will also be disseminated to
guideline committees, NHS organisations and
patient groups.
Trial registration number: 32017426, pre-results.
INTRODUCTION
The ALL-HEART study is an academic clin-
ical trial that aims to address whether allo-
purinol added to usual therapy improves
cardiovascular (CV) outcomes in patients
with ischaemic heart disease (IHD).
IHD is one of the most common causes of
death in men and women in the UK and
most other developed countries.1 Although
death rates from IHD have fallen in the past
10 years, largely due to reductions in
smoking and improvements in treatment and
secondary prevention, morbidity from IHD is
increasing. Patients with IHD often have
reduced quality of life due to symptoms, limi-
tation of activities and psychological impact
of the disease. IHD is usually treated with a
combination of medications, some of which
improve symptoms and some of which
improve survival. In addition, interventional
Strengths and limitations of this study
▪ The ALL-HEART study is a large prospective ran-
domised study designed to answer the question
of whether allopurinol improves cardiovascular
outcomes in patients with ischaemic heart
disease.
▪ The trial is conducted within the normal UK
healthcare setting, providing good external valid-
ity. The end point committee is blinded to treat-
ment allocation.
▪ One limitation of the study is that it does not
include patients with ischaemic heart disease
who are younger than 60 years old.
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procedures such as angioplasty, coronary artery stenting
and coronary artery bypass grafting are used in selected
patients.
Allopurinol is a xanthine oxidase inhibitor that lowers
uric acid levels and is licensed for the prevention of
gout, but is not currently indicated for treating asymp-
tomatic hyperuricaemia. Allopurinol is usually given in
doses of 100–900 mg daily. Xanthine oxidase promotes
oxidative stress which inactivates the antiatherosclerotic
substance nitric oxide. Xanthine oxidase levels are
raised in several conditions including coronary artery
disease.2 Allopurinol has several beneﬁcial effects in CV
disease. It improves endothelial function in patients with
heart failure,3 4 type 2 diabetes5 and smokers,6 reduces
left ventricular mass in patients with IHD7 and reduces
left ventricular hypertrophy in patients with type 2 dia-
betes mellitus8 and chronic kidney disease.9 It also
lowers blood pressure and decreases arterial stiffness
and carotid intima-media thickness progression.7 10–13
Allopurinol reduces the troponin rise in patients under-
going percutaneous coronary intervention following ST
elevation myocardial infarction (MI), which is strong evi-
dence that downstream ischaemic cardiomyocytes stay
alive better during an ischaemic insult in the presence
of allopurinol therapy.14 In patients with angina and
angiographically documented coronary artery disease,
allopurinol 600 mg daily has anti-ischaemic activity in
that it increases exercise time and reduces chest pain.15
In earlier observational studies in patients with hyper-
uricaemia16 and heart failure,17 18 allopurinol use was
associated with reduced mortality. In recent case–control
studies, allopurinol use was associated with a reduced
risk of MI19 and a reduced risk of non-fatal MI.20 In a
recent cohort study in patients with hyperuricaemia,
patients on allopurinol treatment had a lower risk of MI,
stroke or CV death and a lower risk of all-cause mortality
compared with non-users of allopurinol.21 A study con-
ducted in the UK Clinical Practice Research Datalink in
patients aged over 65 years with hypertension showed
that allopurinol use was associated with a signiﬁcantly
lower risk of stroke and cardiac events than in non-
exposed control patients. In this study, treatment with
higher dose allopurinol (deﬁned as 300 mg daily) was
associated with a signiﬁcantly lower risk of stroke and
cardiac events than treatment with a lower dose of allo-
purinol.22 In patients with hypertension and impaired
renal function, allopurinol use was associated with a
lower risk of developing CV disease and all-cause mortal-
ity.23 A long-term follow-up study of a 2-year randomised
trial of 113 patients with chronic kidney disease showed
that long-term treatment with allopurinol may slow the
rate of progression of kidney disease and reduce CV
risk.24 25
Various mechanisms have been suggested as to how
allopurinol may improve CV outcomes. Xanthine
oxidase is a major source of reactive oxygen species.26
Allopurinol profoundly reduces oxidative stress by redu-
cing superoxide anions and other free radicals, which
reduces cardiac hypertrophy, increases tissue oxygen-
ation and reduces atherosclerotic plaque rupture which
is involved in MI.27–30 Allopurinol may also reduce
cardiac afterload by improving arterial compliance
through reduced wave reﬂection and improved endothe-
lial function. It is not clear whether it is uric acid lower-
ing or other effects of allopurinol that are important,
although in one study comparing allopurinol with the
uricosuric agent probenecid, effects on endothelial func-
tion were only seen with xanthine oxidase inhibition
and not by reducing uric acid with probenecid.27 Finally,
by inhibiting xanthine oxidase activity, allopurinol
increases levels of hypoxanthine, which might increase
ATP levels and thus energy availability to tissues. Extra
ATP and oxygen availability produced by allopurinol
might prevent downstream ischaemic cardiomyocytes
from infarcting and thereby leading to heart failure
during an ischaemic insult such as acute coronary syn-
drome (ACS).31 32
Some studies have suggested that higher doses of allo-
purinol (often 600 mg daily) are necessary to achieve
some of the positive CV effects,6–8 15 22 27 which is why a
dose of 600 mg daily was selected for participants with
normal renal function at baseline for the current study.
It has previously been demonstrated that this can be
given safely in patients with angina.15
Most of the papers in this ﬁeld still conclude that
there is a need for large randomised controlled trials to
answer the question of whether allopurinol is beneﬁcial
in patients with CV disease. The ALL-HEART study is
the key outcome study that will provide the answer to
this question in patients with IHD, in addition to provid-
ing robust data on any improvements in quality of life
and an analysis of the health economics of the use of
allopurinol in the UK National Health Service (NHS) in
patients with IHD.
METHODS AND ANALYSIS
Objectives
The primary objective of the study is to determine
whether the addition of allopurinol (up to 600 mg
daily) to usual therapy improves CV outcomes. The sec-
ondary objectives are to determine the cost-effectiveness
of adding allopurinol to usual therapy, to determine
whether allopurinol improves quality of life and to deter-
mine the safety and tolerability of giving allopurinol to
patients with IHD (without a history of gout).
Outcomes
The primary outcome is the composite CV end point of
non-fatal MI, non-fatal stroke or CV death. The second-
ary outcomes are non-fatal MI; non-fatal stroke; CV
death; all-cause mortality; all CV hospitalisations; hospi-
talisation for ACS (includes hospitalisation for MI and
for troponin-negative cardiac chest pain); coronary
revascularisation; hospitalisation for ACS or coronary
revascularisation, hospitalisation for heart failure, quality
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of life (EQ-5D and Seattle Angina Questionnaire); cost-
effectiveness of allopurinol. Data will also be collected
on the safety and tolerability of allopurinol in patients
with IHD, in particular, discontinuations of allopurinol
due to adverse events including gout ﬂares and serious
adverse skin reactions.
Ethics and trial registration
The study received approval from the UK Medicines
and Healthcare products Regulatory Agency (MHRA),
local research and development departments and the
national Caldicott guardian in Scotland. Patient recruit-
ment to the study started on 7 February 2014. The trial
was prospectively registered in ISRCTN (ISRCTN32017426;
16 August 2013) and EudraCT (2013-003559-39;
19 September 2013). Protocol amendments will be
approved by the ethics committee and regulatory author-
ities as per current guidelines and will be communicated
to investigators and the primary trial registry by the
study team.
Study design
The study is a multicentre, controlled, prospective, ran-
domised, open-label, blinded end point (PROBE) super-
iority trial of allopurinol (up to 600 mg daily) versus no
treatment added to usual therapy in patients aged
60 years and over with IHD. The study is end point
driven and will end when the required number of adju-
dicated primary end points have occurred.
Number of participants
In total, 5215 patients will be randomised in a 1:1 ratio
to allopurinol or no additional treatment (ﬁgure 1).
Patients will be recruited from the UK. Approximately
290 primary care practices will be involved, and the
study will be coordinated by two main study sites
(Dundee, Scotland and Nottingham, England).
Recruitment was initially expected to last for ∼2 years
with an expected average follow-up period of 4 years.
The recruitment phase was extended in 2016 and the
follow-up phase may be extended depending on recruit-
ment rates and event rates.
Identification of participants, screening visit and
randomisation
Primary care practice lists are searched for suitable
patients with IHD who are invited to participate. Other
patients with IHD who volunteer to take part in the trial
may be included. Patients may also be invited to partici-
pate from secondary care clinics and consented research
databases. At a screening visit, written informed consent
is taken by a research nurse (or doctor), inclusion and
exclusion criteria checked (box 1) and blood samples
taken for baseline full blood count, urea and
Figure 1 ALL-HEART study overview. In total, 5215 patients aged over 60 years with ischaemic heart disease will be
randomised to receive allopurinol or no additional therapy, in addition to their usual care, then followed up for an expected
average of 4 years for outcomes.
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electrolytes, creatinine, estimated glomerular ﬁltration
rate (eGFR) and urate. Baseline demographics, medical
history, CV risk factors, medication, blood pressure and
height and weight data are collected.
Two different quality of life questionnaires are com-
pleted at the screening visit—the EQ-5D33 to assess
general health outcomes and the Seattle Angina
Questionnaire34 to assess coronary artery disease-speciﬁc
quality of life. The EQ-5D is a standardised instrument
for use as a measure of health outcome. Applicable to a
wide range of health conditions and treatments, it pro-
vides a simple descriptive proﬁle and a single index value
for health status. The Seattle Angina Questionnaire is a
disease-speciﬁc self-administered functional status
measure for patients with coronary artery disease. It mea-
sures ﬁve clinically important dimensions of health in
patients with coronary artery disease (anginal stability,
anginal frequency, physical limitation, treatment satisfac-
tion, quality of life) and is sensitive to clinical change
over time. The (UK) English version is used.
Data are recorded on a secure dedicated electronic
case report form (eCRF) and study web portal with a
central database at the Robertson Centre for
Biostatistics, University of Glasgow. Patients are rando-
mised via a web portal based at the Robertson Centre
for Biostatistics, University of Glasgow or interactive
voice response system in a 1:1 ratio to either allopurinol
or no drug to be given in addition to their usual medica-
tions. No placebo is used in the study; the comparator
arm is usual care. Randomisation is stratiﬁed by primary
care practice, history of MI and history of stroke, with
treatment group allocated according to randomly per-
muted blocks of variable size. The allopurinol (oral
tablet) is prescribed generically by the primary care
physician.
In patients with screening visit blood results showing
eGFR≥60 mL/min, allopurinol is started at 100 mg
daily for 2 weeks, then titrated to 300 mg daily for
2 weeks, then 600 mg daily (given as 300 mg twice
daily) if tolerated. Allopurinol is then continued at
600mg daily, given as 300mg twice daily, (or the
maximum tolerated dose if lower) throughout the dur-
ation of the study for up to 5 years. In patients with
screening visit blood results showing eGFR 30–59 mL/
min, allopurinol is started at 100 mg daily for 2 weeks,
then titrated to 300 mg daily if tolerated. Allopurinol is
then continued at 300 mg daily (or the maximum toler-
ated dose if lower) throughout the duration of the
study for up to 5 years.
Patients with screening visit blood results showing
eGFR 30–59 mL/min were only included in the study
from 4 April 2016 onwards following implementation of
a protocol amendment that aimed to improve recruit-
ment, enrich the study population and increase the gen-
eralisability of the results. Owing to a temporary UK
shortage of allopurinol 100 mg tablet supply experi-
enced in 2014, the protocol was amended to allow
patients to start on 100–150 mg allopurinol for the ﬁrst
2 weeks. The dose was then uptitrated as above. The
usual starting dose of allopurinol for the majority of
patients in the study was 100 mg.
Blood tests are sent to local NHS laboratories and
results are checked and entered into the eCRF by study
nurses. General practitioners (GPs) are alerted to any
abnormal blood results. All patients are asked to report
any adverse events, particularly rash or gout ﬂares. GPs
are also asked to report any serious adverse events that
come to their attention during the trial. Patients experien-
cing a rash that could be due to allopurinol are withdrawn
from allopurinol therapy. Patients withdrawing from allo-
purinol therapy are encouraged to still complete the
planned follow-up within the study. Reasons for with-
drawal from randomised therapy are recorded.
Temporary withdrawals of allopurinol therapy are allowed
at the discretion of a physician and reasons are documen-
ted. Dose changes are also allowed at the discretion of a
physician at any time during the study (up to the
maximum doses speciﬁed within the protocol). Any dose
changes are recorded on the study eCRF and reasons
documented. Patients undergo usual concomitant care
Box 1 Inclusion and exclusion criteria
Inclusion criteria:
1. Male or female patients aged 60 years and over.
2. Ischaemic heart disease (IHD) defined as a diagnosis of
angina or myocardial infarction at any time or other evidence
of IHD (investigator opinion).
Exclusion criteria:
1. History of gout.
2. *Known severe renal impairment (estimated glomerular filtra-
tion rate (eGFR) <30 mL/min).
3. Moderate-to-severe heart failure (New York Heart Association
III–IV).
4. Significant hepatic disease (eg, alanine transaminase>3×
upper limit of normal, cirrhosis, ascites; investigator opinion).
5. Patients currently taking part in another interventional clinical
trial of an investigational medicinal product or medical
device (or taken part in one within the past 3 months).
6. Previous allergy to allopurinol.
7. Previous serious adverse cutaneous (skin) reaction to any
drug (eg, Stevens Johnson syndrome, toxic epidermal necro-
lysis, hospitalisation due to skin reaction to drug; investigator
opinion).
8. Patients already taking urate-lowering therapy (including allo-
purinol, febuxostat, sulfinpyrazone, benzbromarone, probene-
cid, rasburicase).
9. Patients taking azathioprine, mercaptopurine, ciclosporin or
theophylline.
10. Malignancy (except non-metastatic, non-melanoma skin
cancers, cervical in situ carcinoma, breast ductal carcinoma
in situ, or stage 1 prostate carcinoma) within the past
5 years (investigator opinion).
*Exclusion criterion 2 was previously ‘known renal impairment
eGFR<60 mL/min’ for patients recruited from the start of the trial
(7 February 2014) until 4 April 2016 when protocol v4 was imple-
mented at all study sites. Fifty-two per cent of the target number
of patients had been randomised by this date.
4 Mackenzie IS, et al. BMJ Open 2016;6:e013774. doi:10.1136/bmjopen-2016-013774
Open Access
group.bmj.com on November 11, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
during their participation in the trial and no interventions
are prohibited during the trial.
Adverse reactions in association with allopurinol are
rare in the overall treated population and mostly of a
minor nature. The incidence of adverse reactions is
thought to be higher in the presence of renal and/or
hepatic disorders. The most common adverse reaction
to allopurinol is rash (affects around 1% of patients).
Usually this is a minor rash that resolves on stopping
therapy. Rarely, the rash may be more serious and occa-
sionally serious skin reactions such as Stevens Johnson
syndrome or toxic epidermal necrolysis may occur. In
the event of a serious skin reaction, allopurinol therapy
should be stopped immediately and should not be
restarted. Other possible adverse reactions to allopurinol
include gastrointestinal disturbance such as nausea or
vomiting, asymptomatic increases in liver function tests,
hypersensitivity, angio-oedema and hepatitis. The
summary of product characteristics lists other possible
adverse reactions to allopurinol.
All serious adverse events are collected (whether
thought to be related to randomised therapy or not).
Non-serious adverse events (non-serious adverse reac-
tions) are only collected if thought to be possibly, prob-
ably or deﬁnitely related to randomised therapy. Data on
occurrence of skin rashes and gout ﬂares are collected
from all patients in the study. If any patients randomised
to the non-allopurinol arm of the study later start allo-
purinol therapy for clinical reasons, this is recorded on
the eCRF along with the reasons. At the end of the trial,
patients will stop allopurinol therapy and will continue
to receive usual care.
FOLLOW-UP
Six-week study visit
Patients randomised to allopurinol attend a study visit
with a nurse 6 weeks (5–7 weeks) after starting allopur-
inol. At this visit, blood samples are taken for full blood
count, urea and electrolytes, creatinine, eGFR and urate.
Adverse events, concomitant medications, compliance
with allopurinol and dose of allopurinol are recorded at
this visit.
Annual patient questionnaires
Adverse events, skin reactions, gout flares, compliance
Data on adverse events, skin reactions, gout ﬂares and
compliance with randomised therapy are collected by
questionnaire (online, postal or telephone) at annual
intervals throughout the study. Changes can also be
reported to the study team at any time.
Quality of life
Patients complete the EQ-5D and Seattle Angina
Questionnaire quality of life questionnaires after 1 year
and at the end of the trial.
Health service usage
Data on health service usage is collected at 1 year and at
the end of the trial from all participants (and from a
randomly selected 25% of participants at annual inter-
vals during the trial) by email/online where possible or
otherwise by postal questionnaire or telephone. The
patient is asked to report the number of visits they have
made to a primary care physician, practice nurse, physio-
therapist and hospital outpatient clinics over the last
year. The number of hospitalisations is collected separ-
ately via the electronic record linkage system along with
other outcome data.
Record linkage
Record linkage for clinical events and outcomes
Record linkage for clinical events (hospitalisations,
deaths and cancers) will be carried out annually for
patients within the trial using national record linkage
systems in Scotland (Information Services Division
(ISD), NHS National Services Scotland)35 and England
(Health and Social Care Information Centre
(HSCIC)).36 Potential end points will be investigated
further by obtaining information from medical records.
End point packages will be prepared, removing identify-
ing patient details and details of randomised treatment
then adjudicated by an end point committee blinded to
treatment allocation.
DATA ANALYSIS AND STATISTICAL METHODS
Sample size
In total, 5215 patients will be randomised to give 80%
power to detect a 20% reduction in the primary CV end
point for the intervention (allowing for 4% dropout for
withdrawal of consent to follow-up and for non-CV
deaths). A 14% event rate over 4 years average follow-up
has been estimated from previous trials in similar patient
groups. The study will end when 631 adjudicated
primary end points have occurred.
Primary and sensitivity analyses
Data analysis will be carried out according to a predeter-
mined data analysis plan. The ﬁnal trial data set will be
available to the trial statisticians and ALL-HEART investi-
gators. The primary analysis will be intention-to-treat.
The primary outcome and its individual components
(CV death, non-fatal stroke and non-fatal MI) will be
analysed as cause-speciﬁc time to event outcomes using
Cox proportional hazards models. Treatment effects will
be estimated in the form of HRs (allopurinol vs no treat-
ment) with 95% CIs and p values (Wald statistic).
Results will be summarised graphically using cumulative
incidence functions. Prespeciﬁed subgroup analyses will
be carried out by investigating the effects of treatment
within each subgroup with heterogeneity of treatment
effect across subgroup levels assessed by ﬁtting inter-
action terms to the overall Cox models. Prespeciﬁed sub-
groups will include patients with high or normal urate at
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baseline, patients with eGFR≥60 mL/min versus patients
with eGFR 30–59 mL/min at screening visit, patients
with CV or any hospitalisation within the year prior to
entry to the study, patients aged <70 years versus those
aged 70+ years. Results for other CV outcomes and all-
cause mortality will be analysed in a similar manner.
Time to discontinuation of allopurinol treatment will be
described. Serious adverse events will be coded using
MedDRA and tabulated according to system organ class
and preferred term.
Health economic assessment and analysis
The economic evaluation will assess the cost-
effectiveness of adding allopurinol to usual care alone.
The perspective on costs will be that of the NHS plus
social services. A cost-utility analysis will be performed
comparing the difference in costs (net of savings) with
the difference in quality-adjusted life years estimated
using a Markov modelling approach. Transition probabil-
ities will be estimated from the trial data and used to
make projections over the lifetime of the patients.
As described above, data will be collected on CV
events, quality of life (using EQ-5D) and hospital admis-
sions, as well as other resource use. We will estimate
costs using sources such as Healthcare Resource Groups
costs for England and Monthly Index of Medical
Specialities for medicines.
Imputation techniques will be used to estimate the
values for missing data based on the characteristics of
the patient.
Prespeciﬁed subgroup analyses will include patients
with higher than normal range uric acid at baseline
versus patients with normal uric acid at baseline, patients
aged <70 years versus those over 70 years, and patients
with a CV or any hospitalisation in the year prior to entry
to the study versus those without such a hospitalisation.
There will be uncertainty in the data, including sam-
pling variation where data can be measured directly, and
the selection of data from previous studies (eg, costs and
disutility of events). A range of sensitivity analyses will be
carried out including a cost-effectiveness acceptability
curve, but also using threshold analysis and simpler
scenario analyses as appropriate.
Trial management
Trial Steering Committee
A Trial Steering Committee (TSC) oversees the conduct
and progress of the trial. It includes an independent
chair, independent scientiﬁc and lay members and study
investigators. The chair and members of the TSC are
appointed by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) pro-
gramme director according to their standard procedures.
Independent Data Monitoring Committee
An independent Data Monitoring Committee (DMC)
oversees the safety of participants in the trial. The DMC
monitors unblinded comparative data and makes
recommendations to the TSC on whether there are any
ethical or safety reasons why the trial should not con-
tinue. The chair and members of the DMC are
appointed by the NIHR HTA programme director
according to their standard procedures. Planned interim
data analyses will be performed for review by the DMC.
The DMC will have the opportunity to make a recom-
mendation of early stopping because of overwhelming
evidence of beneﬁt from study treatment based on
interim analyses after ∼50% and 75% of the target
number of adjudicated study outcomes have been
observed. Overwhelming evidence of beneﬁt is deﬁned
as evidence of beneﬁt of allopurinol over usual care
(p<0.001). Because of the conservative nature of this
test, these interim analyses will have no impact on the
overall sample size calculations.
Clinical Endpoint Committee
An independent Clinical Endpoint Committee (CEC)
will adjudicate all primary end points within the trial
and selected categories of secondary end points and is
blinded to treatment allocation. The chair and members
of the CEC are appointed by the sponsor.
Study sponsorship, trial monitoring, audit and quality
assurance
The trial is sponsored by the University of Dundee and
NHS Tayside. Email: tasctayside@nhs.net. Trial monitor-
ing is carried out by the sponsor according to a trial-
speciﬁc monitoring plan. The sponsor also undertakes
audit and quality assurance activities for the trial.
Dissemination plan
The results of the trial will be reported in peer-reviewed
journals and at scientiﬁc meetings. Results will also be
disseminated to guideline committees, NHS organisa-
tions and patient groups. Participants will be informed
of the main trial results via a letter or newsletter and
main results will be posted on the ALL-HEART study
public website (http://www.allheartstudy.org). An
authorship and acknowledgements policy has been
approved by the TSC. No use of professional writers is
intended. The protocol will be made publicly available
on the NIHR website (http://www.nihr.ac.uk) and will
be included as a supplementary ﬁle at the time the
main trial results are published.
CONCLUSIONS
On a background of many years of supportive evidence
for the potential beneﬁts of allopurinol in CV disease,
the ALL-HEART study is a key outcome study that
should answer the question of whether adding allopur-
inol therapy to usual care in patients with IHD aged
over 60 years improves major CV outcomes. It will also
provide important information on quality of life, safety
of allopurinol in this patient population and health
economics.
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